RAM
REGN icon

Readystate Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Readystate Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$773K Buy
+1,000
New +$766K 0.03% 358
2025
Q1 		– Sell
-300
Closed -$214K – 720
2024
Q4 		$214K Sell
300
-12,900
-98% -$10.8M 0.01% 574
2024
Q3 		$13.9M Buy
13,200
+12,800
+3,200% +$14.2M 0.26% 133
2024
Q2 		$420K Sell
400
-10,400
-96% -$10.1M 0.01% 566
2024
Q1 		$10.4M Buy
10,800
+10,400
+2,600% +$9.89M 0.15% 170
2023
Q4 		$351K Buy
400
+100
+33% +$82.3K 0.01% 501
2023
Q3 		$247K Hold
300
– – 0.01% 474
2023
Q2 		$216K Sell
300
-100
-25% -$77.1K 0.02% 269
2023
Q1 		$329K Buy
+400
New +$302K 0.03% 195

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Readystate Asset Management's REGN Position: Q4 2024 in Review

Readystate Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 5,482 shares — an estimated $4.6M sold.

Readystate Asset Management first reported a position in REGN in Q3 2024 and held it in 1 quarter. The position peaked at $5.76M in Q3 2024. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • Readystate Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Readystate Asset Management sold 5,482 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $4.6M.
  • Readystate Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Readystate Asset Management's Regeneron Pharmaceuticals position peaked at $5.76M in Q3 2024.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Readystate Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.